Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
Though lung cancer looks promising a partner is now needed.
The company’s AN9025 will shortly enter phase 1.
But the group still hopes to get IGV-001 approved based on overall survival data.
